CClinicalTrials.gg
RecruitingNCT06373289PHOXUpdated Aug 26, 2026

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

An interventional study of higher oxygen saturation target using Nellcor pulse oximetry sensors and lower oxygen saturation target using Nellcor pulse oximetry sensors in Bronchopulmonary Dysplasia and Pulmonary Hypertension, sponsored by University of Alabama at Birmingham. Recruiting at 2 sites in United States. Open to participants aged 1 Month to 5 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
1 Month to 5 Months
Sex
All
01

Study summary

Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.

Read the detailed description

Infants born between 22.0 to 31.6 weeks' gestational age with bronchopulmonary dysplasia associated pulmonary hypertension, are receiving supplemental oxygen, and have mature retinas will be randomized to SpO2 targets of either (1) 92-95% (control) or (2) 95-98% (intervention).

Using a cross over design with a 1:1 parallel allocation of infants randomized using a stratified permuted block design. Following 1week of exposure A, infants will cross over to exposure B for 1 week with a 1-week washout period. Bedside providers will follow pre-specified algorithms to maintain oxygen targets during the randomization period. Reports of oxygen saturation performance will also be provided to bedside providers through oxygen saturation histograms.

02

Conditions studied

  • Bronchopulmonary Dysplasia
  • Pulmonary Hypertension
03

Who can participate

Ages eligible
1 Month to 5 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Between 22w 0/7d and 31w 6/7d gestation at birth
  • Diagnosed with echocardiographic pulmonary hypertension (1) >20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index >1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
  • Receiving supplemental oxygen
  • Have mature retinas

Exclusion criteria

Exclusion Criteria:

  • Major congenital anomalies
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
39 participants (estimated)

Study arms

  • Active comparator
    Oxygen saturation target 92-95%

    At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 92-95% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed to a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets.

    Device: lower oxygen saturation target using Nellcor pulse oximetry sensors

  • Active comparator
    Oxygen saturation target 95-98%

    At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 95-98% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed for a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets.

    Device: higher oxygen saturation target using Nellcor pulse oximetry sensors

Interventions

  • Devicehigher oxygen saturation target using Nellcor pulse oximetry sensors

    The intervention will be a cross over exposure to the higher oxygen saturation target.

  • Devicelower oxygen saturation target using Nellcor pulse oximetry sensors

    The intervention will be a cross over exposure to the lower oxygen saturation target.

05

What researchers measure

Primary outcomes

  1. Intermittent hypoxemia event duration

    The average duration of time (in seconds) an infant's oxygen saturation decrease below 80%.

    Time frame: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first

Secondary outcomes

  1. Echocardiographic shunting

    \>20% flow of blood across the PDA from the pulmonary to arterial circulation

    Time frame: through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first

  2. Echocardiographic interventricular septal flattening

    End-systolic flattening of the interventricular septum (eccentricity index \>1.3)

    Time frame: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first

  3. Echocardiographic tricuspid regurgitation

    Right ventricular pressure estimates

    Time frame: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first

  4. Intermittent hypoxemia frequency

    Number of daily events during which an infant's oxygen saturation decreases below 80%

    Time frame: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first

  5. Cumulative hypoxemia

    Daily duration during which an infant's oxygen saturation is \<80%

    Time frame: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first

  6. Brain natriuretic peptide

    A polypeptide released from the cardiac ventricles indicative of right heart strain

    Time frame: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first

06

Study locations

2 of 2 sites recruiting
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06373289
Lead sponsor
University of Alabama at Birmingham
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Responsible party
Samuel Gentle (Assistant Professor, Yale University) — Principal investigator
First posted
Apr 18, 2024
Start date
Sep 15, 2026 (estimated)
Primary completion
Jul 6, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Aug 26, 2026

Study contacts

Samuel Gentle, MD
Contact
samjgentle@gmail.com
205-541-2247
Colm Travers
Contact
samuel.gentle@yale.edu
Samuel Gentle
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion